Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (181-190 of 372) with videos related to

Pageof 38
Sort By:
Journal of Virology|July 24, 2024
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I allelesGeorge W Nelson, Janine van Duijn, Yuko Yuki, et al.
AIDS (London, England)|January 31, 2003
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infectionStephanie A Mulherin, Thomas R O'Brien, John P Ioannidis, et al.
AIDS (London, England)|November 26, 2019
Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ARTMichael A Eller, Ting Hong, Matthew Creegan, et al.
Human Immunology|October 12, 2021
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in ThailandRasmi Thomas, Danaya Chansinghakul, Kriengsak Limkittikul, et al.
BMC Public Health|October 2, 2024
HIV incidence and its associated factors among young adults with multiple sexual partners in Maputo, Mozambique: a vaccine preparedness studyIvalda Macicame, Nilesh Bhatt, Edna Viegas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2019
New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With MenErik Billings, Gustavo H Kijak, Eric Sanders-Buell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 13, 2018
Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular ClonesAgnes-Laurence Chenine, Melanie Merbah, Lindsay Wieczorek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2012
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeMark S de Souza, Silvia Ratto-Kim, Weerawan Chuenarom, et al.
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.
Ebiomedicine|October 4, 2023
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, et al.
Pageof 38

Showing results (181-190 of 372) with videos related to

Sort By:
Pageof 38
Journal of Virology|July 24, 2024
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I allelesGeorge W Nelson, Janine van Duijn, Yuko Yuki, et al.
AIDS (London, England)|January 31, 2003
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infectionStephanie A Mulherin, Thomas R O'Brien, John P Ioannidis, et al.
AIDS (London, England)|November 26, 2019
Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ARTMichael A Eller, Ting Hong, Matthew Creegan, et al.
Human Immunology|October 12, 2021
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in ThailandRasmi Thomas, Danaya Chansinghakul, Kriengsak Limkittikul, et al.
BMC Public Health|October 2, 2024
HIV incidence and its associated factors among young adults with multiple sexual partners in Maputo, Mozambique: a vaccine preparedness studyIvalda Macicame, Nilesh Bhatt, Edna Viegas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2019
New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With MenErik Billings, Gustavo H Kijak, Eric Sanders-Buell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 13, 2018
Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular ClonesAgnes-Laurence Chenine, Melanie Merbah, Lindsay Wieczorek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2012
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeMark S de Souza, Silvia Ratto-Kim, Weerawan Chuenarom, et al.
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.
Ebiomedicine|October 4, 2023
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, et al.
Pageof 38